Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines
Liyan Guo, Sheng Lin, Zimin Chen, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 42
Nucleoside‐Based Drug Target with General Antimicrobial Screening and Specific Computational Studies against SARS‐CoV‐2 Main Protease
Sarkar M. A. Kawsar, Md. Ahad Hossain, Supriyo Saha, et al.
ChemistrySelect (2024) Vol. 9, Iss. 15
Closed Access | Times Cited: 12
Fragment-based screening targeting an open form of the SARS-CoV-2 main protease binding pocket
Chia‐Ying Huang, A. Metz, Roland Lange, et al.
Acta Crystallographica Section D Structural Biology (2024) Vol. 80, Iss. 2, pp. 123-136
Open Access | Times Cited: 6
The Envelope (E) Protein of SARS-CoV-2 as a Pharmacological Target
Teresa Santos-Mendoza
Viruses (2023) Vol. 15, Iss. 4, pp. 1000-1000
Open Access | Times Cited: 18
Innate and adaptive immunity to SARS-CoV-2 and predisposing factors
Jiaying Shen, Junyan Fan, Yue Zhao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review
Ya-Qi Xiao, Jiao Long, Shuang‐Shuang Zhang, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107380-107380
Closed Access | Times Cited: 5
Small Molecule Drugs Targeting Viral Polymerases
Deborah Palazzotti, Martina Sguilla, Giuseppe Manfroni, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 661-661
Open Access | Times Cited: 5
Ubiquitin Ligase Parkin Regulates the Stability of SARS-CoV-2 Main Protease and Suppresses Viral Replication
Li Zhou, Ruochuan Liu, Heather Pathak, et al.
ACS Infectious Diseases (2024) Vol. 10, Iss. 3, pp. 879-889
Open Access | Times Cited: 4
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control
Shen Wang, Wujian Li, Zhenshan Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 4
Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population
Vivek P. Chavda, Divya Teli, Pankti C. Balar, et al.
Molecules (2023) Vol. 28, Iss. 5, pp. 2332-2332
Open Access | Times Cited: 13
Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study
Xiang Zhao, Yuan Cheng, Meng Zhang, et al.
Infection and Drug Resistance (2023) Vol. Volume 16, pp. 6053-6060
Open Access | Times Cited: 12
Synthesis, molecular docking analysis, molecular dynamic simulation, ADMET, DFT, and drug likeness studies: Novel Indeno[1,2-b]pyrrol-4(1H)-one as SARS-CoV-2 main protease inhibitors
Davood Gheidari, Morteza Mehrdad, Mohammad Bayat
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0299301-e0299301
Open Access | Times Cited: 3
Gold nanoparticles combat enveloped RNA virus by affecting organelle dynamics
Fangzhou Li, Qianqian Huang, Ziran Zhou, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 10
Molecules for COVID-19 treatment
Zhigang Zeng, Changzhou Liao, Lei Yu
Chinese Chemical Letters (2023) Vol. 35, Iss. 7, pp. 109349-109349
Closed Access | Times Cited: 10
An Overview on Anti-COVID-19 Drug Achievements and Challenges Ahead
Mehdi Valipour, Hamid Irannejad, Hossein Keyvani
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 9, pp. 1248-1265
Open Access | Times Cited: 8
Microfluidic-assisted single-cell RNA sequencing facilitates the development of neutralizing monoclonal antibodies against SARS-CoV-2
Ziwei Wang, Amelia Siqi Huang, Lingfang Tang, et al.
Lab on a Chip (2024) Vol. 24, Iss. 4, pp. 642-657
Open Access | Times Cited: 2
Anti-Viral Activity of Bioactive Molecules of Silymarin against COVID-19 via In Silico Studies
Chunye Zhang, Yuxiang Sui, Shuai Liu, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 10, pp. 1479-1479
Open Access | Times Cited: 7
Fourteen immunomodulatory alkaloids and two prenylated phenylpropanoids with dual therapeutic approach for COVID-19: molecular docking and dynamics studies
Rowida Omar, Mohamed Abd El-Salam, Marwa Elsbaey, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 5, pp. 2298-2315
Open Access | Times Cited: 6
Identification of Potential TMPRSS2 Inhibitors for COVID-19 Treatment in Chinese Medicine by Computational Approaches and Surface Plasmon Resonance Technology
Rong Yang, Linhua Liu, Dansheng Jiang, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 10, pp. 3005-3017
Closed Access | Times Cited: 6
Therapeutic prospects of naturally occurring p38 MAPK inhibitors tanshinone IIA and pinocembrin for the treatment of SARS‐CoV‐2‐induced CNS complications
Mehdi Valipour
Phytotherapy Research (2023) Vol. 37, Iss. 9, pp. 3724-3743
Closed Access | Times Cited: 6
A novel nanobody broadly neutralizes SARS‐CoV‐2 via induction of spike trimer dimers conformation
Yang Yang, Junfang Zhang, Shengnan Zhang, et al.
Exploration (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 6
Safety Profile of Paxlovid in the Treatment of COVID-19
Bing Lv, Xin Gao, Guoqiang Zeng, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 9, pp. 666-675
Closed Access | Times Cited: 1
Bruton's tyrosine kinase inhibition for the treatment of allergic disorders
Erica V. Lin, Ragha Suresh, Melanie C. Dispenza
Annals of Allergy Asthma & Immunology (2024) Vol. 133, Iss. 1, pp. 33-42
Open Access | Times Cited: 1
Analogs of the Catechol Derivative Dynasore Inhibit HIV-1 Ribonuclease H, SARS-CoV-2 nsp14 Exoribonuclease, and Virus Replication
Abhishek Asthana, Angela Corona, Woo-Jin Shin, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1539-1539
Open Access | Times Cited: 5
NMR Characterization of the Papain-like Protease from SARS-CoV-2 Identifies the Conformational Heterogeneity in Its Inhibitor-Binding Site
Yutaro Shiraishi, Ichio Shimada
Journal of the American Chemical Society (2023) Vol. 145, Iss. 30, pp. 16669-16677
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top